S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.58 (+0.33%)
AAPL   174.09 (-0.26%)
MSFT   290.09 (-0.42%)
META   174.55 (-0.17%)
GOOGL   120.10 (+0.46%)
AMZN   142.34 (+0.17%)
TSLA   908.45 (-0.39%)
NVDA   187.80 (+2.43%)
NIO   19.87 (-1.05%)
BABA   90.71 (+1.05%)
AMD   100.49 (+2.26%)
MU   63.08 (+2.37%)
T   18.40 (-0.11%)
CGC   3.80 (-6.40%)
F   16.14 (+0.69%)
GE   79.23 (-0.86%)
DIS   122.55 (-0.21%)
AMC   19.06 (-10.77%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.83 (+1.53%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.58 (+0.33%)
AAPL   174.09 (-0.26%)
MSFT   290.09 (-0.42%)
META   174.55 (-0.17%)
GOOGL   120.10 (+0.46%)
AMZN   142.34 (+0.17%)
TSLA   908.45 (-0.39%)
NVDA   187.80 (+2.43%)
NIO   19.87 (-1.05%)
BABA   90.71 (+1.05%)
AMD   100.49 (+2.26%)
MU   63.08 (+2.37%)
T   18.40 (-0.11%)
CGC   3.80 (-6.40%)
F   16.14 (+0.69%)
GE   79.23 (-0.86%)
DIS   122.55 (-0.21%)
AMC   19.06 (-10.77%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.83 (+1.53%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.58 (+0.33%)
AAPL   174.09 (-0.26%)
MSFT   290.09 (-0.42%)
META   174.55 (-0.17%)
GOOGL   120.10 (+0.46%)
AMZN   142.34 (+0.17%)
TSLA   908.45 (-0.39%)
NVDA   187.80 (+2.43%)
NIO   19.87 (-1.05%)
BABA   90.71 (+1.05%)
AMD   100.49 (+2.26%)
MU   63.08 (+2.37%)
T   18.40 (-0.11%)
CGC   3.80 (-6.40%)
F   16.14 (+0.69%)
GE   79.23 (-0.86%)
DIS   122.55 (-0.21%)
AMC   19.06 (-10.77%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.83 (+1.53%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.58 (+0.33%)
AAPL   174.09 (-0.26%)
MSFT   290.09 (-0.42%)
META   174.55 (-0.17%)
GOOGL   120.10 (+0.46%)
AMZN   142.34 (+0.17%)
TSLA   908.45 (-0.39%)
NVDA   187.80 (+2.43%)
NIO   19.87 (-1.05%)
BABA   90.71 (+1.05%)
AMD   100.49 (+2.26%)
MU   63.08 (+2.37%)
T   18.40 (-0.11%)
CGC   3.80 (-6.40%)
F   16.14 (+0.69%)
GE   79.23 (-0.86%)
DIS   122.55 (-0.21%)
AMC   19.06 (-10.77%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.83 (+1.53%)
NASDAQ:RCKT

Rocket Pharmaceuticals - RCKT Stock Forecast, Price & News

$17.35
-0.29 (-1.64%)
(As of 08/18/2022 03:59 PM ET)
Add
Compare
Today's Range
$16.56
$17.38
50-Day Range
$9.80
$18.32
52-Week Range
$7.57
$37.44
Volume
19,472 shs
Average Volume
702,944 shs
Market Capitalization
$1.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.80

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
229.2% Upside
$55.80 Price Target
Short Interest
Bearish
14.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.25mentions of Rocket Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.94) to ($2.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

541st out of 1,122 stocks

Pharmaceutical Preparations Industry

268th out of 551 stocks

RCKT stock logo

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

Analyst Ratings Changes

RCKT has been the topic of several research reports. William Blair reaffirmed an "outperform" rating on shares of Rocket Pharmaceuticals in a research report on Thursday, May 5th. Raymond James upped their target price on Rocket Pharmaceuticals from $22.00 to $24.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th. Needham & Company LLC decreased their target price on Rocket Pharmaceuticals from $75.00 to $62.00 and set a "buy" rating on the stock in a research report on Tuesday, May 17th. Stifel Nicolaus upped their target price on Rocket Pharmaceuticals from $63.00 to $67.00 in a research report on Thursday, May 19th. Finally, Chardan Capital upped their target price on Rocket Pharmaceuticals from $60.00 to $62.00 and gave the company a "buy" rating in a research report on Thursday, May 19th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $55.80.

Rocket Pharmaceuticals Trading Down 1.6 %

Shares of RCKT Stock opened at $17.64 on Thursday. The stock has a 50 day simple moving average of $14.74 and a 200 day simple moving average of $14.38. The company has a current ratio of 13.41, a quick ratio of 13.41 and a debt-to-equity ratio of 0.05. Rocket Pharmaceuticals has a 1 year low of $7.57 and a 1 year high of $37.44. The stock has a market cap of $1.16 billion, a P/E ratio of -5.92 and a beta of 1.68.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Rating) last released its earnings results on Monday, August 8th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.16). During the same period in the previous year, the company posted ($0.55) earnings per share. On average, research analysts predict that Rocket Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Stock News Headlines

Rocket League codes (July 2022)
See More Headlines
Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Company Calendar

Last Earnings
8/08/2022
Today
8/18/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RCKT
Employees
151
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$55.80
High Stock Price Forecast
$67.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+221.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-169,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.89 per share

Miscellaneous

Free Float
43,670,000
Market Cap
$1.14 billion
Optionable
Optionable
Beta
1.68

Key Executives

  • Dr. Gaurav D. Shah M.D. (Age 47)
    CEO & Director
    Comp: $920.2k
  • Ms. Kinnari Patel M.B.A. (Age 43)
    MBA, Pharm.D., PharmD, Pres & COO
    Comp: $717.82k
  • Mr. Martin L. Wilson J.D. (Age 45)
    Gen. Counsel, Chief Compliance Officer & Sr. VP
    Comp: $149.95k
  • Mr. Jonathan Schwartz (Age 58)
    Chief Medical Officer & Sr. VP of Clinical Devel.
    Comp: $557.79k
  • Mr. John C. Militello CPA (Age 49)
    CPA, Interim Principal Financial Officer, VP, Sr. Controller, Treasurer & Principal Accounting Officer
  • Mayur Kasetty M.B.A.
    M.D., Bus. Devel. & Operations and Investor Relations Lead
  • Ms. Jessie Yeung M.B.A.
    VP of Investor Relations & Corp. Fin.
  • Kevin Giordano
    Director of Corp. Communications
  • Ms. Isabel Carmona J.D.
    Sr. VP & Chief HR Officer
  • Dr. Gayatri R. Rao J.D.
    M.D., Chief Devel. Officer of LVV & Sr. VP













RCKT Stock - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings
or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price forecast for 2022?

6 brokerages have issued 12-month price targets for Rocket Pharmaceuticals' shares. Their RCKT share price forecasts range from $24.00 to $67.00. On average, they predict the company's stock price to reach $55.80 in the next twelve months. This suggests a possible upside of 216.3% from the stock's current price.
View analysts price targets for RCKT
or view top-rated stocks among Wall Street analysts.

How have RCKT shares performed in 2022?

Rocket Pharmaceuticals' stock was trading at $21.83 at the start of the year. Since then, RCKT shares have decreased by 19.2% and is now trading at $17.64.
View the best growth stocks for 2022 here
.

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our RCKT earnings forecast
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its earnings results on Monday, August, 8th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by $0.16. During the same period last year, the company earned ($0.55) earnings per share.

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (3.85%), Assenagon Asset Management S.A. (2.57%), Price T Rowe Associates Inc. MD (2.14%), JPMorgan Chase & Co. (1.29%), Franklin Resources Inc. (1.01%) and GMT Capital Corp (0.75%). Insiders that own company stock include Gaurav Shah, Gotham Makker, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends
.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $17.64.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.16 billion. The biotechnology company earns $-169,070,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

The company employs 151 workers across the globe.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (646) 440-9100, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.